Previous clinical trials have shown that pembrolizumab monotherapy more effectively improved the OS of advanced NSCLC patients without programmed death‐ligand 1 (PD‐L1) expression and oncogenic epidermal growth factor receptor (EGFR), or anaplastic lymphoma kinase (ALK) mutations compared with platinum‐based chemotherapy.8, 9. Here, ALK is linked to non-small cell lung carcinoma.